Bernard Silverman, M.D.

Dr. Bernard Silverman is a seasoned biotechnology professional with over 20 years of experience in clinical development and team building. Since 2019, he has been consulting for innovative biotechnology firms, including serving as Chief Medical Officer for companies such as Lyndra Therapeutics, Nirsum Therapeutics, and Nocion Therapeutics. In these roles, he has been instrumental in advancing clinical programs and has aided in the recruitment of Chief Medical Officers.

Prior to his consulting career, Dr. Silverman spent nearly two decades at Alkermes, where he held various leadership positions across Clinical Development, Drug Safety, and Medical Affairs. He played key roles in the development and approval of several significant medications, including VIVITROL® for alcohol and opioid use disorders, ARISTADA®, ARISTADA INITIO®, and LYBALVI®. Additionally, he led clinical development efforts for several inhaled therapies, such as insulin, levodopa, salmeterol, fluticasone and growth hormone.

Before joining Alkermes, Dr. Silverman was an Associate Professor of Pediatrics at Northwestern University and was the Head of the Division of Pediatric Endocrinology at the Children’s Memorial Hospital in Chicago. He also served as a member of the Institutional Review Board. He received his B.A. in Biophysics from the University of Pennsylvania and his M.D. from Mount Sinai School of Medicine. He has authored numerous publications in peer-reviewed journals and served on the American Board of Pediatrics’ General Pediatrics Examination Committee. Throughout his career, Dr. Silverman has been passionate about mentoring, particularly through his involvement in the Women Unlimited LEAD program.